Education
About Us
Working with TipRanks
Follow Us
Evonik (DE:EVK)
XETRA:EVK
Top Page
Evonik
(XETRA:EVK)
55Neutral
Positive Factors
Guidance
The CEO expressed confidence in the FY-25 guidance, with a solid start in Q1 and expectations for EBITDA to increase year-over-year.
Innovation
Innovation growth areas have achieved their targets, with significant sales and margin increases, and new targets set for 2032.
Tariffs
Evonik is resilient to US tariffs, as the company benefits from high tariffs on Chinese methionine imports to the US.
Negative Factors
Industry Changes
Structural changes in the European chemical industry indicate that 15-20% of value chains are lost and will not return, leading to plant closures.
Quarterly Performance
Q4 EBITDA was lower than expected due to one-time effects, with all segments below expectations except for Others.
Evonik (EVK) vs. S&P 500 (SPY)
Market Cap
€9.19B
Dividend Yield5.87%
Average Volume (3M)982.48K
Price to Earnings (P/E)41.4
Beta (1Y)0.90
Revenue Growth-0.72%
EPS GrowthN/A
CountryDE
Employees30,669
SectorIndustrials
Sector Strength78
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.48
Shares Outstanding466,000,000
10 Day Avg. Volume750,204
30 Day Avg. Volume982,481
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.12Price Target Upside11.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Evonik Business Overview & Revenue Model
Company DescriptionEvonik Industries AG is a leading global specialty chemicals company based in Germany. The company operates in several sectors including Nutrition & Care, Resource Efficiency, and Performance Materials, offering a diverse range of products such as additives, specialty polymers, and chemical intermediates. Evonik's core products are used in various industries including pharmaceuticals, automotive, construction, and consumer goods, providing innovative solutions that enhance the performance and sustainability of its clients' products.
How the Company Makes MoneyEvonik makes money primarily through the sale of specialty chemicals and related products across its key business segments: Nutrition & Care, Resource Efficiency, and Performance Materials. The company generates revenue by providing high-value, innovative chemical products that meet specific customer needs, often under long-term contracts. Its earnings are bolstered by strategic partnerships and collaborations with industry leaders, allowing Evonik to leverage its expertise and expand its market reach. Additionally, the company's focus on research and development enables it to continuously innovate and maintain a competitive edge in the specialty chemicals market.
Evonik Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 15.16B | 15.27B | 18.49B | 14.96B | 12.20B | Gross Profit |
| 3.74B | 3.39B | 4.23B | 4.03B | 3.37B | EBIT |
| 0.00 | 630.00M | 1.43B | 1.24B | 886.00M | EBITDA |
| 1.76B | 1.73B | 2.07B | 2.18B | 1.76B | Net Income Common Stockholders |
| 222.00M | -465.00M | 540.00M | 746.00M | 465.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 618.00M | 1.03B | 1.12B | 919.00M | 1.06B | Total Assets |
| 19.75B | 21.26B | 21.81B | 22.28B | 20.90B | Total Debt |
| 3.78B | 4.25B | 4.23B | 3.64B | 3.84B | Net Debt |
| 3.32B | 3.50B | 3.58B | 3.19B | 3.27B | Total Liabilities |
| 10.65B | 12.28B | 10.75B | 12.91B | 12.80B | Stockholders Equity |
| 9.02B | 8.91B | 10.97B | 9.29B | 8.01B |
| Cash Flow | Free Cash Flow | |||
| 873.00M | 801.00M | 785.00M | 929.00M | 771.00M | Operating Cash Flow |
| 1.71B | 1.59B | 1.65B | 1.81B | 1.73B | Investing Cash Flow |
| -663.00M | -653.00M | -777.00M | -1.07B | -570.00M | Financing Cash Flow |
| -1.33B | -823.00M | -672.00M | -856.00M | -1.73B |
Evonik Technical Analysis
Positive
19.87
Price Trends
19.89
Negative
18.78
Positive
19.10
Positive
Market Momentum
0.05
Negative
55.95
Neutral
77.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EVK, the sentiment is Positive. The current price of 19.87 is above the 20-day moving average (MA) of 18.93, below the 50-day MA of 19.89, and above the 200-day MA of 19.10, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 55.95 is Neutral, neither overbought nor oversold. The STOCH value of 77.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EVK.
Evonik Peers Comparison
Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.35B | 13.89 | 5.37% | 4.22% | -10.63% | -23.15% | |
67 Neutral | €5.19B | 19.57 | 15.87% | 2.44% | 2.58% | 8.02% | |
64 Neutral | $4.27B | 11.80 | 5.31% | 249.79% | 4.07% | -9.02% | |
58 Neutral | €2.27B | ― | -3.92% | 0.36% | -5.18% | -139.96% | |
56 Neutral | €39.62B | 53.61 | 2.02% | 7.74% | -2.04% | 2258.97% | |
55 Neutral | €9.19B | 41.39 | 2.47% | 5.87% | -0.72% | ― | |
47 Neutral | €2.76B | 91.49 | -1.05% | 4.50% | -5.67% | -133.79% |
* Industrials Sector Average
Performance Comparison
DE:EVK
Evonik
19.87
0.71
3.70%
DE:SDF
K+S Aktiengesellschaft
15.66
2.30
17.17%
DE:BAS
BASF SE
42.38
-5.16
-10.86%
DE:WCH
Wacker Chemie AG
65.80
-36.62
-35.75%
DE:FPE3
Fuchs Petrolub
45.48
2.52
5.86%
DE:LXS
LANXESS
25.92
-2.61
-9.14%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.